logo
logo

Watchmaker Genomics Raises $40M Series A Financing To Accelerate Growth And Expand Clinical Sequencing Product Offerings

Jun 02, 2022•about 3 years ago

Amount Raised

$40 Million

Round Type

series a

BoulderOther

Description

Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing, and editing of DNA and RNA, today announced it had secured $40 million in an oversubscribed Series A, bringing total funding to date to $53.5 million. The round was led by Decheng Capital, with co-investment from Eclipse Ventures.

Company Information

Company

Watchmaker Genomics

Location

Boulder, Colorado, United States

About

The company launched its first product in 2020 and has since achieved profitability with 175% year-over-year revenue growth. In addition, the company will expand commercial channels and manufacturing capacity, making these product solutions more broadly accessible to the life science and genomics communities. "We are thrilled to partner with Watchmaker Genomics as the company enters its next phase of product innovation and commercialization. "Decheng Capital is a leading investor in life science and sequencing, and we are excited to have the firm lead our Series A. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People